MDT Medtronic Plc

IMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces an Investigation of Medtronic plc and Advises Investors with Losses to Contact the Firm

LOS ANGELES--(BUSINESS WIRE)--

Lundin Law PC, a shareholder rights firm, announces that it is investigating claims against Medtronic plc (“Medtronic” or the “Company”) (NYSE: MDT) concerning possible violations of federal securities laws.

To get more information about this investigation, please contact Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or by email at [email protected].

On July 17, 2017, Medtronic disclosed that a computer crash on June 19, 2017, which shut down the Company’s global ordering, fulfillment, and manufacturing systems, would crimp its quarterly sales. When this information was announced, shares of Medtronic fell in value.

Lundin Law PC was founded by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

EN
19/07/2017

Underlying

MDTMedtronic Plc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Medtronic Plc

EUR 152.21
MDT MEDTRONIC PLC

Medtronic, plc: Key facts and statistics - LTM October 2025

A summary company profile, detailing Medtronic plc’s business operations and financial highlights.

12/15/25 December 15, 2025 1 EN
Free Trial
MDT MEDTRONIC PLC

Medtronic Plc: 1 director

A director at Medtronic Plc sold 30,000 shares at 101.948USD and the significance rating of the trade was 80/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly ...

11/21/25 November 21, 2025 1 EN
Research Team ACF
  • Research Team ACF
DXCM DEXCOM INC.
VRTX Vertex Pharmace... ... (+19)

KDST + NLSP Combined Core Investment Case 29052025

We consider the merged platform Kadimastem (KDST.TA) + NLS Pharmaceutics (NLSP:NasdaqCM). We provide an investment case analysis and a selection of merged metrics prior to any synergies. The merger creates a cross-platform pre-revenue biotech with lead programs including a proprietary stem-differentiation platform capable of delivering scalable therapies for replacing lost or damaged cells; IsletRx could revolutionize insulin production for Type 1 diabetes (T1D) patients; AstroRx® targets neurod...

DXCM DEXCOM INC.
VRTX VERTEX PHARMACEUTICALS INCORPORATED
TDOC TELADOC HEALTH INC.
PODD INSULET CORPORATION
ORMP ORAMED PHARMACEUTICALS
MDT MEDTRONIC PLC
LLY ELI LILLY AND COMPANY
SAN SANOFI
TILS TIZIANA LIFE SCIENCES
CRSP CRISPR THERAPEUTICS AG
SENS SENSEONICS HOLDINGS
TNDM TANDEM DIABETES CARE
NOVO NOVO NORDISK A/S-B
SANA SANA BIOTECHNOLOGY
HIMS HIMS AND HERS HEALTH INC (A)
KDST.TA:TASE KADIMASTEM
NLSP:NasdaqCM NLS PHARMACEUTICS
CRSP (NASDAQ) CRISPR THERAPEUTICS
TLSA TIZIANA LIFE SCIENCES LTD
05/29/25 May 29, 2025 1 EN
Research Team ACF
  • Research Team ACF
DXCM DEXCOM INC.
VRTX Vertex Pharmace... ... (+19)

ACF Thematic Research Regenerative Medicine Diabetes Treatment & Innov...

Diabetes mellitus, Type 1 (T1D) and Type 2 (T2D, 85-90% of cases), is a USD ~75bn global therapy market. Global economic costs of diabetes may exceed USD1 trn today and USD 450bn in the US, suggesting a pressing global health challenge. Diabetes is a chronic metabolic disorder characterized by high blood sugar levels. In 2024, consensus global estimates suggested there were ~800m adult diabetes sufferers. In 2021, according to the IDF there >530m sufferers globally. For 2027E we modestly forecas...

DXCM DEXCOM INC.
VRTX VERTEX PHARMACEUTICALS INCORPORATED
TDOC TELADOC HEALTH INC.
PODD INSULET CORPORATION
ORMP ORAMED PHARMACEUTICALS
MDT MEDTRONIC PLC
LLY ELI LILLY AND COMPANY
SAN SANOFI
TILS TIZIANA LIFE SCIENCES
CRSP CRISPR THERAPEUTICS AG
SENS SENSEONICS HOLDINGS
TNDM TANDEM DIABETES CARE
NOVO NOVO NORDISK A/S-B
SANA SANA BIOTECHNOLOGY
HIMS HIMS AND HERS HEALTH INC (A)
KDST.TA:TASE KADIMASTEM
NLSP:NasdaqCM NLS PHARMACEUTICS
CRSP (NASDAQ) CRISPR THERAPEUTICS
TLSA TIZIANA LIFE SCIENCES LTD
03/13/25 March 13, 2025 1 EN
Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke
EUR 42.28
SNYN SANOFI S.A. ADS
NTRA NATERA ... (+20)

Vermilion Compass: Weekly Equity Strategy

S&P 500 Holding Above Prior Breakout Level Yet Again As discussed throughout the first half of January, we continue to believe that tariffs will mostly be used as a negotiation tactic, and much like Trump's prior presidency, will be much less impactful than feared. We reiterated this in yesterday's pre-market ETF Pathfinder, also noting "we anticipate the Canada/Mexico tariffs to be resolved relatively quickly, and therefore we view the latest pullback as a buying opportunity." Sure enough, bot...

SNYN SANOFI S.A. ADS
NTRA NATERA
MMSI MERIT MEDICAL SYSTEMS INC.
MDT MEDTRONIC PLC
LINC LINCOLN EDUCATIONAL SERVICES
FMS FRESENIUS MEDICAL CARE AG & CO. KGAA ADS
BMY BRISTOL-MYERS SQUIBB COMPANY
APEI AMERICAN PUBLIC EDUCATION
BSX. BELO SUN MINING CORP.
PEN PANORO ENERGY ASA
UTI UNIVERSAL TECHNICAL INSTITUTE INC.
LAUR LAUREATE EDUCATION INC. CLASS A
ATGE ADTALEM GLOBAL EDUCATION INC.
DGS. DIVIDEND GROWTH SPLIT
GH GUARDANT HEALTH
STRA STRATEGIC EDUCATION INC.
LRN STRIDE INC
LH LABCORP HOLDINGS INC
GSK GSK PLC
PROD PROSVETNO DELO AD ORD
02/04/25 February 4, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch